Palvella Therapeutics (NASDAQ:PVLA) executives used the company’s full-year 2025 financial results call to highlight clinical progress across its rare disease pipeline, outline upcoming regulatory and commercial milestones for its lead program, and discuss a financing that management said positions the company to pursue a first U.S. product launch.
2025 milestones and early 2026 momentum
Founder and CEO Wes Kaupinen said 2025 was “a landmark year” for Palvella, citing multiple development and corporate milestones. These included positive Phase II data in cutaneous venous malformations (CVM) supporting a “near-term Breakthrough Therapy designation submission to FDA and a pivotal phase III study,” and enrollment that surpassed targets in the Phase III SELVA study in microcystic lymphatic malformations (MLM).
Heading into 2026, Kaupinen said Palvella announced positive Phase III SELVA data in MLM and completed a $230 million financing earlier in 2026. He said the company plans to add two more diseases to the pipeline by year-end, bringing the number of diseases it aims to treat to six.
Lead program: QTORIN rapamycin in microcystic lymphatic malformations
Kaupinen said Palvella believes MLM represents a “significant multibillion-dollar commercial opportunity,” citing an estimate of more than 30,000 diagnosed U.S. patients, based on claims analysis and published literature. He added the company estimates roughly 1,500 new patients are diagnosed each year and is concentrating early commercial efforts on approximately 400 high-volume centers the company estimates represent about half of the diagnosed population.
On SELVA, Kaupinen said the Phase III study exceeded the company’s “predefined upside case” across measured dimensions. On the primary endpoint (MLM Investigator Global Assessment), he said the outcome was “highly statistically significant.” He added that 95% of patients completing the efficacy evaluation period improved and 86% were “much improved or very much improved.” He said the blinded key secondary endpoint (MLM MCSS) was also highly statistically significant. From a safety perspective, he said QTORIN rapamycin was “well-tolerated in both children and adults,” and highlighted retention, noting that 98% of week 24 completers elected to roll into the extension period.
On regulatory plans, Kaupinen said Palvella is “on track for NDA submission in the second half of 2026,” with “potential FDA approval targeted for the first half of 2027.” He said the company recently submitted its pre-NDA meeting request to FDA’s Division of Dermatology and Dentistry, with the meeting anticipated in the second quarter of 2026. Kaupinen emphasized the company is pursuing “a traditional full FDA approval based on clinical endpoints,” rather than an accelerated approval approach. He also said Palvella intends to pursue a label including patients aged 3 and above and plans to use a 505(b)(2) pathway.
During Q&A, Kaupinen addressed questions about reliance on a single-arm, baseline-controlled Phase III design, saying Palvella believed it was aligned with FDA before and remains aligned, citing the disease’s lack of spontaneous regression and the use of clinical outcomes that compare end-of-treatment assessments to baseline photos. He described interactions with FDA as “constructive” and said the company is proceeding toward the pre-NDA meeting.
Commercial planning and pricing expectations
Kaupinen said Palvella anticipates orphan pricing “consistent with our previous guidance of $100,000-$200,000 per patient per year.” He said the company has built an experienced commercial foundation, highlighting Kline’s prior launch experience with OXERVATE and the addition of Jennifer McDonough to lead market access and patient services, citing her involvement in the launch of Krystal Biotech’s VYJUVEK.
On launch buildout, Kaupinen said the company is hiring medical science liaisons and expects an MSL team of “somewhere between 5 and 10.” He also said Palvella expects to hire a head of sales in the near term and reiterated a “provisional range of 20-40 sales reps,” adding that following the recent financing, the company is “more likely to go to the upper end” of that range.
Asked about dosing assumptions for modeling, Kaupinen said Palvella expects the “average patient will be 1 pump per day” with chronic therapy, while CFO Matt Korenberg said the company’s peak sales commentary uses conservative assumptions and that variations around one pump per day are expected to be more than offset by new incident patients entering the population each year.
Pipeline updates: CVM, angiokeratomas, and DSAP
For cutaneous venous malformations, Kaupinen said Palvella reported positive Phase II data in December 2025 with statistically significant results across clinician and patient-reported outcomes. He said 73% of patients improved on the CVM Investigator Global Assessment and 67% were “much improved or very much improved” at week 12. The company plans to initiate a Phase III study in the second half of 2026, with study design alignment expected mid-2026.
Palvella is also preparing a Breakthrough Therapy designation application for CVM. In response to an analyst question, Kaupinen said Phase II extension data were “not yet finalized” and would not be part of the Breakthrough submission. He said the submission will include the Phase II dataset, patient qualitative interviews, and a letter of support from investigators.
Chief Scientific Officer Dr. Jeff Martini said the Phase II angiokeratomas trial is “ahead of schedule,” with initiation anticipated in the second quarter. He described angiokeratomas as sharing overlapping features with MLMs and said the indication has “more than 50,000 diagnosed patients in the U.S.” with no FDA-approved therapies. On study design, Kaupinen and Martini said the Phase II angiokeratomas trial will be a signal-finding study without a prespecified statistical hierarchy and will evaluate multiple clinician- and patient-focused endpoints, including qualitative interviews.
Martini also reviewed QTORIN pitavastatin in disseminated superficial actinic porokeratosis (DSAP), calling DSAP “chronic, progressive, and precancerous” and noting there are no FDA-approved therapies. He said Palvella expects to initiate a Phase II study in the second half of 2026. In Q&A, Martini said DSAP genetics are “very well characterized” with loss-of-function mutations in genes involved in the mevalonate pathway, and referenced prior work including a topical lovastatin study showing clinical response and the company’s review of published studies. He added that Palvella’s formulation work addressed stability challenges seen with some statins, aiming for “very stable formulation and consistent delivery at therapeutic concentrations with low systemic absorption.”
Kaupinen said the company expects to announce an additional QTORIN rapamycin indication and a new QTORIN product candidate in the second half of 2026, and Martini said Palvella plans to pursue FDA platform technology designation following anticipated approval of QTORIN rapamycin.
Financial position and cash burn outlook
CFO Matt Korenberg said Palvella ended 2025 with $58 million in cash and cash equivalents. He said the company completed an “oversubscribed $230 million public offering” in February 2026, generating $215.8 million in net proceeds and resulting in pro forma cash of $274 million.
Korenberg said the financing “eliminates financing overhang” and, even before potential revenue, funds the company through an NDA filing, potential approval, and a U.S. launch for the MLM program, while also supporting a Phase III program and an NDA filing for CVM and multiple Phase II readouts across the pipeline. He guided to “somewhere around $80 million of cash burn” for 2026.
About Palvella Therapeutics (NASDAQ:PVLA)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
